Regeneron rises after strong Q2 beat powered by high-dose Eylea
I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) shares rose in premarket trading after reporting Q2 2026 results that beat street estimates. The company posted $4.2 billion in revenue, driven primarily by strong sales of its new high-dose Eylea eye therapy.
Shares of Regeneron Pharmaceuticals (REGN) gained in the premarket on Thursday after the U.S. drugmaker reported Q2 2026 results exceeding the Street estimates comfortably, mainly due to higher sales from the new high-dose version of its eye therapy, Eylea. The Tarrytown, New York-based firm reported $4.2B in revenue for the quarter, indicating ~17...